In order to achieve a high efficiency of gene delivery into rare cell types like stem cells the use of viral vectors is presently without alternative. An ideal stem cell gene therapy vector would be able to infect primitive progenitor cells and sustain or activate gene expression in differentiated progeny. However, many viral vectors are inactivated when introduced in developing systems where cell differentiation occurs. To this end, we have developed a mouse in vitro model for testing herpesvirus saimiri (HVS)-based gene therapy vectors. We demonstrate here for the first time that HVS is able to infect totipotent mouse embryonic stem (ES) cells with high efficiency. We have transduced ES cells with a
Introduction
Pluripotent haematopoietic stem cells (HSCs) represent important targets for gene therapy because of their capacity to act as genetic reservoirs for the correction of specific defects apparent in differentiated progeny. The ideal vector for HSCs would be able to transduce these cells efficiently and either maintain transgene expression throughout differentiation, or contain all the necessary regulatory information to activate stably a transgene at the appropriate cell differentiation stage. In order to develop and study such a vector, it is necessary to carry out experiments in a relevant system which resembles potential applications as closely as possible.
The mouse is widely used as a model to study human diseases and potential therapeutic applications. Mouse embryonic stem (ES) cells are totipotent, and can be injected into blastocysts in order to generate transgenic mice. They can also be differentiated in vitro into various cell types of the haematopoietic system by the addition of specific cytokines. 1, 2 The genetic modification of ES cells can thus be used to study gene function in normal haematopoiesis. This includes the examination of the expression pattern of cell type-specific promoters [3] [4] [5] recombinant virus carrying the enhanced green fluorescent protein (EGFP) gene and the neomycin resistance gene (NeoR) driven by a CMV promoter and the SV40 promoter, respectively. ES cells maintain the viral episomal genome and can be terminally differentiated into mature haematopoietic cells. Moreover, heterologous gene expression is maintained throughout in vitro differentiation. Besides its obvious use in gene therapy, this unique expression system has wide ranging applications in studies aimed at understanding gene function and expression in cell differentiation and development. Gene Therapy (2000) 7, 464-471.
to haematopoietic development by means of targeted mutagenesis (reviewed in Refs 6 and 7). These features render ES cells an ideal means to study stem cell gene therapy vectors for the haematopoietic system.
Owing to their efficiency of gene delivery, viral vectors at present are without alternative for gene therapy of HSCs. Retroviral vectors are currently the most commonly used system for HSC transduction. However, the analysis of retroviral vectors in the murine ES cell model has been severely hampered by two blocks to permissive provirus expression. The first is a partial repression in the undifferentiated ES cell state, accompanied by increased methylation but compatible with long-term, low-level expression of retroviral genes. The second is a chromatinmediated repression and extinction of expression which occurs during the early stages of differentiation, which can only be reversed by histone deacetylase inhibitors. 8 In addition, the packaging capacity of retroviral vectors is extremely limited, thus prohibiting the introduction of the large arrays of genetic information necessary for the correct regulation of eukaryotic genes.
Recombinant adenovirus has been used to infect Zona Pellucida-free mouse eggs at the pronucleus stage. 9 A proportion of the infected eggs gave rise to transgenic mice which were found to contain adenovirus DNA in their genomes. Some of these mice were also found to express the transgene (in this case ␤-galactosidase) at various levels throughout their tissues. This indicates that in contrast to retroviruses, the adenovirus genome is not inactivated during development. However, as with all gene constructs integrated into the host genome, the expression level is strongly affected by genomic position effects, which, dependent on the integration site of the transgene lead to an extensive variability in transcription. 10 Until now no experiments using mouse ES cells have been reported.
We have been investigating the potential of a non-human herpesvirus, herpesvirus saimiri (HVS), as a human gene therapy vector. 11 HVS is the prototype member of the gamma-2 herpesvirus genus (Rhadinoviruses), 12, 13 and shows significant homology at the genomic level with the only known human member of the genus, human herpesvirus 8 or Kaposi's sarcomaassociated herpesvirus.
14,15 HVS strains have been subdivided into three groups (A, B and C) on the basis of their oncogenic potential and the sequence of the open reading frame encoding the HVS transformation-associated protein (STP). 16, 17 Infection of human blood lymphocytes and thymocytes with strains of subgroup C, in contrast to subgroup A which was used in these studies, yields continuously proliferating T cell lines. 18, 19 This virus has also been shown to be capable of infecting a wide variety of human cells in a stable manner. 20, 21 One of the advantages of herpesviruses as gene therapy vectors is their ability to accommodate large arrays of heterologous DNA, certainly far exceeding the packaging capacity of a retro-or adenovirus (reviewed in Ref. 22) . Since the HVS genome is established in an episomal state in the target cell, it could, therefore, theoretically combine the efficiency of a viral delivery system with the features of an artificial chromosome, thus alleviating the influence of genomic positioning effects. Previously, it was not known whether HVS was capable of infecting murine cells. In this report, we describe the development of a murine experimental model, based on ES cells, which allows the development of HVS-based gene therapy vectors. We show that a recombinant HVS is capable of infecting mouse ES cells, that its viral genome is stably maintained as an episome during cell differentiation and most importantly, that expression of an heterologous gene can be detected throughout the differentiation of totipotent stem cells into terminally differentiated progeny.
Results

Recombinant HVS efficiently infects mouse ES cells and is stably propagated
The replication-competent recombinant virus (HVS-EGFP/Neo) used to infect mouse embryonic stem cell was constructed as described in Figure 1 . HVS-EGFP/Neo carries the Neomicin resistance (NeoR) gene driven by the SV40 promoter and a second gene coding for enhanced green fluorescent protein (EGFP) under the control of the human CMV enhancer/promoter ( Figure 1 ). Both genes and their control and poly A regions encompass a sequence array of about 8 kb which was inserted into a site spanning the junction between the unique and the repeat regions of the HVS genome by homologous recombination in OMK cells.
The experimental strategy used to examine the gene expression from recombinant viruses is described in Figure 2 . ES cells were infected with HVS-EGFP/Neo at a multiplicity of infection (MOI) of 1 and stably infected Gene Therapy clones were selected in the presence of G418. These experiments demonstrate for the first time that mouse ES cells can efficiently be infected by a recombinant HVS. As judged by EGFP expression, initial transduction efficiencies of up to 20% could be routinely achieved (data not shown). Figure 3 shows colonies of cells growing on a feeder layer of STO cells, all of which express the EGFP gene at a high level displaying intense fluorescence under G418 selection (Figure 3b ). The presence of the virus had no apparent effect on the cell/colony morphology of the transduced ES cells, which was indistinguishable from nontransduced controls. Mouse ES cells are apparently nonpermissive for virus replication, since no infectious virus could be recovered from the culture supernatant of these cells using a conventional virus recovery assay (data not shown).
Recombinant HVS expresses transgenes throughout the entire ES cell differentiation
After several passages in the presence of G418, ES cells that were stably transduced with HVS-EGFP/Neo were seeded into semi-solid in vitro differentiation cultures under conditions which promoted macrophage development.
3 Figure 3 shows examples of ES cells and embryoid bodies captured at various stages of differentiation under both normal and blue light. At the time of seeding in the absence of G418, all of the ES cells expressed EGFP. However, shortly after the onset of ES cell differentiation a dynamic, but obviously stochastic EGFP expression pattern could be observed. Early in the differentiation process at day 2, small groups of fluorescent cells were visible, which rapidly developed into large embryoid bodies by day 8. As these matured, differences in EGFP expression became more pronounced. In some instances the whole of the embryoid body was bright green, whereas in others not a single fluorescent cell could be seen. Around 15% of seeded cells went on to form embryoid bodies. Figure 3i and j shows an example in which the majority of the embryoid body is non-fluorescent, with the exception of an extremely bright green patch in the centre. By day 16, cells resembling terminally differentiated macrophages could be clearly seen migrating from the embryoid bodies as previously described (Figure 3k , l).
Further analysis was performed on in vitro differentiated cells in order to demonstrate the identity of migrating cells as macrophages. Figure 4a shows examples of cells which were produced by the differentiation of ES cells stably transduced by HVS-EGFP/Neo. Under normal light the vast majority of cells exhibited macrophagelike morphology. We have previously demonstrated that, under the culture conditions used in the experiment, small numbers of fibroblasts can be found in association with the macrophage population. 3 The arrow identifies such a fibroblast. Figure 4b shows the same field viewed under blue light, confirming that while most of the cells expressed EGFP, the degree of fluorescence was variable. In order to obtain proof by functional analysis that the cells were indeed macrophages, we tested their ability to phagosize beads. When beads were added to the culture medium, the cells were seen to engulf large numbers of them (Figure 4c ). Taken together, our experiments demonstrate that the presence of EGFP expressing recombinant virus does not interfere with cell differentiation. Moreover, it can be stably maintained throughout the entire ontogeny, from the totipotent cell to the terminally differentiated macrophage.
The HVS episome is stably maintained during ES cell differentiation but the EGFP expression pattern in differentiating embryoid bodies is dynamic The stochastic expression pattern of the CMV enhancer driven EGFP gene could be explained in three ways: Firstly, it may be possible that the episomal viral genome is not stably maintained during ES cell differentiation and is progressively lost. In order to assess the status and relative amounts of the HVS-EGFP/Neo genome in the ES cells, both before and after differentiation, episomes were isolated from the equal numbers of cells by HIRT extraction and analyzed by Southern blotting. Figure 5a shows the EtBr stained gel and Figure 5b the Southern blot probed by the EcoD fragment of the HVS genome. 23 The EtBr stained gel showed a very small amount of contaminating genomic DNA in the lanes containing undifferentiated and differentiated normal ES cells. However, much brighter episomal bands were seen in the lanes containing HVS-EGFP/Neo-transduced ES cell DNA. When the Southern blot was analysed with a virus-specific probe, no signal was seen with normal ES cell DNA, whereas intense bands were seen in the virus-transduced lanes. The intensities of the signals were comparable, indicating that the copy number of episomes was similar in both undifferentiated and differentiated cells. It is extremely difficult to exclude the possibility that some integration of the HVS genome had occurred in a subpopulation of the selected cells. The absence of a signal from the genomic fraction may be due to the limited sensitivity of the assay used. Conversely, some cross-contamination between episomal and genomic fractions could be reasonably expected, perhaps generating a false positive. However, our results suggest that the vast Secondly, expression may be progressively silenced during cell differentiation by epigenetic mechanisms as previously observed with retroviral constructs. Last, but not least, in the absence of selection, the simple CMV enhancer-promoter combination driving the EGFP gene may act as a binary on-off switch which is differentially, but stochastically responsive to the changing intracellular microenvironment in the differentiating embryoid body. Such a stochastic behaviour of gene expression driven by simple enhancer-promoter combinations has been observed in other systems and can be molecularly explained by a differential stability of transcription factor complexes. 24, 25 The second model would predict that expression would not only be silenced, but would also be switched on again. We therefore studied the develop-a c b 32 
Figure 4 Functional analysis of macrophage phenotype. (a) Examples of cells generated by macrophage in vitro differentiation, the arrow identifies a fibroblast; (b) the same microscopic field under blue light showing variable green phenotype of EGFP-transduced cells; (c) normal illumination of a field of terminally differentiated cells to which beads have been added. This field is shown under normal illumination because the large numbers of beads within the cells blocked out green fluorescence under blue light. All analysis was carried out using a Zeiss Axiovert microscope at 100× magnification.
Figure 5 HVS-EGFP/Neo episome analysis in both undifferentiated and differentiated cells. High molecular weight episomal DNA was isolated from cultures by HIRT extraction, run on a 0.8% agarose gel and Southern blotted on to a nylon membrane. The blot was then probed with
P-labelled EcoD fragment of the HVS genome. Lanes 1-4, EtBr stained gel; lanes 5-8 Southern blot. Lanes 1 and 5, undifferentiated normal ES cells; lanes 2 and 6, differentiated normal ES cells; lanes 3 and 7, undifferentiated HVS-EGFP/Neo-transduced ES cells; lanes 4 and 8, differentiated HVS-EGFP/Neo transduced ES cells.
ment of individual embryoid bodies over the course of the differentiation experiment. Figure 6 shows an example of such an analysis photographed under normal and blue light illumination over the period of embryoid development between day 7 and day 15.
At day 7 the embryoid body exhibited virtually no green fluorescence, but then expression was switched on and increased to detectable levels by day 9, and was stronger still by day 12. The pattern of expression also appeared to alter within the embryoid body over this period, with the lower left region being significantly brighter on day 12 than on day 9. At day 15 EGFP expression was almost lost as the macrophages began to migrate away from it.
The gene silencing phenomenon observed in developing embryoid bodies was not exclusively associated with cell differentiation, but was also observed with undifferentiated ES cells grown without the presence of neomycin. Figure 7 shows a flow cytometric analysis of ES cells grown for 9 days in the presence or absence of neomycin. Initially, 70% of cells demonstrated green fluorescence, whereas after 9 days without selection the percentage of EGFP expressing cells dropped to 44.6%, indicating that gene silencing occurs at a lower rate than in EBs.
In summary, our results clearly demonstrate that HVS episomes are stably maintained under our in vitro differentiation conditions, but that EGFP expression (in the context of the current vector) in differentiating ES cells is a dynamic process.
Discussion
Embryonic stem cells retain the ability to be induced to differentiate into all cell types found in an embryonic and adult mouse in vivo, and can be induced to differentiate into many cell types in vitro. These characteristics have made them invaluable tools for the study of the genetics of development and render them an ideal model for the testing of potential human gene therapy vectors. Until now, no viral gene delivery system has been described which was capable of transducing ES cells with high efficiency and maintaining expression of a transgene throughout differentiation.
In this study we have demonstrated that a recombinant herpesvirus saimiri, expressing EGFP and NeoR, is capable of infecting ES cells with high efficiency in a stable manner. The addition of G418 to the medium allowed the establishment of a pure population of transduced cells, all of which expressed EGFP. In addition, the transduced cells grew in an apparently normal manner which was directly comparable with nontransduced wild-type cells. One obvious continuation of these studies is the generation of transgenic mice using HVS-transduced ES cells.
To this end, we have successfully repeated this work using a recombinant virus based on the S4 strain of HVS which is incapable of transforming any cell type and is therefore more suitable for in vivo studies. 26 In addition, although no infectious virus was detected in cultures of either undifferentiated or differentiated cells, suggesting that the infection is abortive or latent in nature, it will be desirable to generate replication disabled viruses for these and other gene therapy-related studies. Such vectors are currently being developed in our laboratories.
Long-term maintenance and cell type-specific gene expression are of great relevance to the field of gene therapy and stem cell gene therapy in particular. It is therefore appropriate to consider the observations made in this study in some detail.
Upon differentiation of HVS-transduced ES cells and in the absence of G418 selection, embryoid bodies were formed with high efficiency. However, it was at this point that EGFP expression was modulated, although EBs descend from one individual cell clone and in methylcellulose cultures they originate from one individual ES cell. Potential reasons for this lack of expression included the loss of the virus genome upon cell division and the modulation of gene expression through epigenetic effects. Our experiments clearly demonstrate that the latter is true. However, the partial inactivation of EGFP expression by epigenetic mechanisms differs from the silencing phenomenon observed with retroviruses stably integrated into the genome. Instead, our results are reminiscent of studies which describe a binary model of enhancer-promoter interaction. In these experiments, expression from a simple enhancer-promoter-reporter gene combination randomly integrated as a single copy gene into the host genome was examined on the single cell level. 24, 25 It was found that in the absence of selection the stability of expression, not the expression level, was differentially modulated by chromatin-mediated genomic position effects. Expression was progressively silenced after multiple rounds of cell division.
In our system, the integration site of the EGFP into the virus genome is always the same. However, the virus epi-some is, most probably, also packaged into chromatin which is able to exert epigenetic effects on the expression of inserted transgenes. We could indeed demonstrate that in ES cells, as well as in a variety of other cultured cells of fixed differentiation states, in the absence of G418 selection EGFP expression was progressively silenced in a cell type-dependent fashion, even though the viral episome was retained (unpublished observation). This and our observation that EGFP expression in EBs can also be switched on again, suggests that the most important epigenetic influence on the stability of EGFP transcription in differentiating embryoid bodies is the fact that the nuclear environment is changing during cell differentiation. Differential genomic position effects affecting genes inserted at the same chromosomal position, but examined in different cell types, have been demonstrated before. 27 The different cellular EGFP expression levels that we observe can be explained by the fact that the viral genome is present in multiple copies, which may oscillate between an active and an inactive state. This phenomenon has recently been observed with reporter gene constructs stably transfected at the same chromosomal position and has been demonstrated to be caused by epigenetic effects. 28 We and others have previously shown that complete genomic loci carrying a complete set of cis-regulatory elements have the capacity to sustain developmentally stable gene expression (reviewed in Refs 29 and 30). A similar herpesvirus gene delivery system based on Epstein-Barr virus has recently been shown to be able to accommodate more than 100 kb of human sequences, however, this virus is unable to infect murine cells. 31 The transgenic sequence array inserted into HVS examined in this study spans around 8 kb, however, the HVS genome has been shown to be able to accommodate at least 40 kb of foreign sequence. 20 It will thus enable the use of complex regulatory regions which, in contrast to simple enhancer-promoter combinations, are unaffected by epigenetic silencing and are sufficient to confer high-level, tissue-specific and developmentally stable gene expression.
HVS has the potential to alleviate many of the problems associated with current gene therapy vectors because of its ability to infect a wide variety of human cells (including early human haemopoietic progenitor cells 11 ) and maintain its genome episomally upon cell division. Together with its ability to accommodate large genomic inserts, it has the characteristics of an efficiently delivered artificial chromosome. The features of the HVS vector system that have been demonstrated in this study suggest that it may be particularly useful in the treatment of haematological disorders. Vectors could be constructed in which the expression of the therapeutic gene was under the control of a complete and correctly expressed cell type-specific cis-regulatory region. Such constructs should activate the therapeutic gene only in the desired cell type. Haematopoietic stem cells could then be isolated from the patient, infected with the virus in vitro and re-infused. This strategy would provide a reservoir of treated cells (the stem cells) which could be of long-lasting therapeutic value to the patient. The same features would also make the vector useful in the developing field of human stem cell biology, assuming that the characteristics of the vector were transferrable from the murine context. In summary, the HVS-transduced model of in vitro ES cell differentiation may provide an informative system for the study of gene therapy vectors designed to express heterologous genes from a variety of cell specifically expressed gene loci. Such studies are currently under way.
Materials and methods
ES cell culture and differentiation Cells of ES line CCE 32 were cultured on a layer of mitomycin-treated G418-resistant STO fibroblasts in 85% standard Dulbecco's modified Eagle's medium (Gibco, Paisley, UK), 15% FCS (Gibco) supplemented with 0.15 mm a-monothioglycerol (MTG) and 25 mm Hepes buffer. 0.3% of medium conditioned by 8/24 720 LIF-D CHO cells (Genetics Institute, Cambridge, MA, USA) was added as a source of LIF. In vitro differentiations were performed in methyl cellulose media with IL-1, IL-3 and M-CSF as described. 3 Recombinant human IL-1a used at 250 U/ml was obtained from Dr P Lomedico (HoffmannLa Roche, Nutley). Medium conditioned by X63 Ag8-653 myeloma cells carrying an IL-3 expression vector 33 was used at 5%. Mouse L-cell conditioned medium was added at 5-10% as a source of M-CSF. For macrophage culture the differentiated cells were transferred to bacteriological Petri dishes in standard Iscove's modified Dulbecco's medium (Gibco), 10% FCS supplemented with 0.15 mm MTG, 5% IL-3 medium and10% L-cell conditioned medium.
Virus construction
The plasmid construct pJEGFPNeo, containing the EGFP gene under the control of the CMVIE promoter and the NeoR gene under the control of the SV40 promoter, was inserted into the HVS genome at a site spanning the junction between the unique and the repeat regions via a single crossover event in the 3′ 1.8 kb unique region of the HVS genome. This was achieved by transfecting owl monkey kidney (OMK) cells with the vector, infecting with replication-competent wt HVSA11 at a MOI of 1, 24 h later, and harvesting virus which grew in medium containing G418. Green plaques were then isolated and subjected to two further rounds of plaque purification. To check that the heterologous DNA had recombined in a site-specific manner the DNA from recombinant and wild-type viruses was digested with EcoRV and NotI, Southern blotted, and probed with a 32 P-labelled EGFP fragment (labelled using a random priming kit (Amersham Pharmacia Biotech, St Albans, UK)).
Infection of ES cells
ES cells were infected with HVS-EGFP/Neo at a MOI of 1. Infection was carried out in a volume of 0.5 ml for 1 h at 37°C after which the cells were cultivated on STO feeder layers in the presence of 600 g/ml G418. STO cells are inherently resistant to this agent but only those ES cells which were stably transduced by the virus were able to grow, resulting in a population which was 100% green and G418 resistant.
Flow cytometry ES cells were harvested from the respective cultures by trypsinisation to generate a single cell suspension. The cells were fixed in PBS containing 1% paraformaldehyde before passing through a Coulter (Miami, FL, USA) Epics XL-MCL flow cytometer. The majority of ES cells were found to form a bright population of homogenous cells when viewed in the forward/sideward scatter mode and could thus be gated away from the STO fibroblasts also present in the culture.
Episome analysis by Southern blotting HIRT extraction 34 was performed on 1 × 10 7 undifferentiated or differentiated cells, allowing the separation of high molecular weight episomal DNA from genomic material. The episomal DNA fraction was run on an 0.8% agarose gel at 5.5 V/cm for 11 h in 1 × TBE and transferred to a nylon membrane. The filter was probed with the EcoD fragment of the HVS genome, labelled using the random priming method (Amersham Pharmacia Biotech).
